NZ621221A - Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof - Google Patents
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereofInfo
- Publication number
- NZ621221A NZ621221A NZ621221A NZ62122111A NZ621221A NZ 621221 A NZ621221 A NZ 621221A NZ 621221 A NZ621221 A NZ 621221A NZ 62122111 A NZ62122111 A NZ 62122111A NZ 621221 A NZ621221 A NZ 621221A
- Authority
- NZ
- New Zealand
- Prior art keywords
- bendamustine
- formulations
- combination
- histone deacetylase
- deacetylase inhibitor
- Prior art date
Links
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 3
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002707 bendamustine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical group O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/051470 WO2013039488A1 (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ621221A true NZ621221A (en) | 2016-07-29 |
Family
ID=47883567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ621221A NZ621221A (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9492423B2 (OSRAM) |
| EP (1) | EP2755648B1 (OSRAM) |
| JP (1) | JP6330118B2 (OSRAM) |
| KR (1) | KR101892788B1 (OSRAM) |
| CN (1) | CN103917231B (OSRAM) |
| AU (1) | AU2011376953B2 (OSRAM) |
| CA (1) | CA2845806C (OSRAM) |
| ES (1) | ES2627820T3 (OSRAM) |
| MX (1) | MX365393B (OSRAM) |
| NZ (1) | NZ621221A (OSRAM) |
| RU (1) | RU2609833C2 (OSRAM) |
| SG (1) | SG2014014419A (OSRAM) |
| UA (1) | UA110853C2 (OSRAM) |
| WO (1) | WO2013039488A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2626067A1 (en) | 2006-12-26 | 2013-08-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| AU2015356779A1 (en) * | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
| WO2016205695A1 (en) * | 2015-06-19 | 2016-12-22 | Faller Douglas V | Methods and compositions for treating herpesvirus induced conditions |
| US20200179381A1 (en) * | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| CN114209667A (zh) | 2016-04-08 | 2022-03-22 | 赛伦诺科技有限公司 | 包含丙戊酸的延迟释放药物制剂和其用途 |
| KR20220100077A (ko) | 2016-04-21 | 2022-07-14 | 발큐리아 에이비 | 암의 예비치료용 조성물 및 방법 |
| EP4650005A2 (en) | 2016-07-15 | 2025-11-19 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| WO2018068832A1 (en) | 2016-10-11 | 2018-04-19 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| GB201706544D0 (en) * | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| NZ749727A (en) * | 2018-01-05 | 2020-07-31 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| EP3897626B1 (en) | 2018-12-18 | 2025-09-10 | Mundipharma International Corporation Limited | Tinostamustine for treating multiple myeloma |
| SG11202113215UA (en) | 2019-05-31 | 2021-12-30 | Viracta Subsidiary Inc | Methods of treating virally associated cancers with histone deacetylase inhibitors |
| WO2022159852A1 (en) * | 2021-01-25 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Methods and compositions for treating adenoid cystic carcinoma |
| TW202423402A (zh) * | 2022-10-21 | 2024-06-16 | 美商維拉克塔股份有限公司 | Hdac抑制劑化合物之投藥方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126375A (en) | 1964-03-24 | Chioacyl | ||
| US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
| US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
| US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
| US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
| BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
| SE378110B (OSRAM) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
| SE378109B (OSRAM) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3775656A (en) | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
| CH581818A5 (OSRAM) | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
| US4498038A (en) | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| DE3889545T2 (de) | 1987-10-20 | 1994-10-13 | Otsuka Pharma Co Ltd | Phenylcarbonsäure-abkömmlinge. |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤 |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| DE4124345A1 (de) | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
| CA2122479C (en) | 1991-11-22 | 1998-08-25 | Richard John Dansereau | Risedronate delayed-release compositions |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung von wachsmatrizes |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| US5448938A (en) | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6718130B2 (en) | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
| AU774734B2 (en) | 1999-05-28 | 2004-07-08 | David E. Grober | Autonomous, self leveling, self correcting stabilized platform |
| EP1204868A1 (en) | 1999-08-10 | 2002-05-15 | Pangene Corporation | Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| BR0014073A (pt) | 1999-09-17 | 2002-07-16 | Abbott Gmbh & Co Kg | Pirazolopirimidinas como agentes terapêuticos |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001038322A1 (en) | 1999-11-23 | 2001-05-31 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| US6888027B2 (en) | 2000-09-29 | 2005-05-03 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| EP1506962B1 (en) | 2000-10-20 | 2008-07-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing aromatic heterocycles |
| EP1358353B1 (en) | 2000-12-28 | 2007-06-20 | Epidauros Biotechnologie AG | Identification of genetic determinants of polymorphic cyp3a5 expression |
| MXPA01013172A (es) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| ATE432068T1 (de) | 2001-06-28 | 2009-06-15 | Ucb Farchim Sa | Cetirizin und pseudoephedrin enthaltende tablette |
| US7247426B2 (en) | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| PT1426054E (pt) | 2001-08-21 | 2011-12-06 | Astellas Pharma Inc | Utilização medicinal de inibidor da histona desacetilase e método de avaliação do seu efeito antitumoral |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030166026A1 (en) | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| EP1472379A1 (en) | 2002-02-04 | 2004-11-03 | Epidauros Biotechnologie AG | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications |
| AU2003211362A1 (en) | 2002-02-21 | 2003-09-09 | Osaka Industrial Promotion Organization | N-hydroxycarboxamide derivative |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| CN1684957A (zh) | 2002-08-02 | 2005-10-19 | 阿根塔发明有限公司 | 作为组蛋白脱乙酰酶抑制剂的取代的噻吩基－异羟肟酸 |
| EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
| US6769347B1 (en) | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
| CA2519320A1 (en) | 2003-02-19 | 2004-09-02 | Astellas Pharma Inc. | Method of estimating antitumor effect of histone deacetylase inhibitor |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| EP1608628A2 (en) | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CN1768031A (zh) * | 2003-04-07 | 2006-05-03 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
| HRP20090487T1 (hr) | 2003-04-07 | 2009-12-31 | Pharmacyclics | Hidroksamati kao terapeutski agensi |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| SI2263694T1 (sl) | 2003-09-25 | 2013-09-30 | Astellas Pharma Inc. | Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin |
| US20070099190A1 (en) | 2003-11-04 | 2007-05-03 | Martin Dugas | Method for distinguishing leukemia subtypes |
| CA2549324A1 (en) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
| JP2007527247A (ja) | 2004-03-05 | 2007-09-27 | ロゼッタ インファーマティクス エルエルシー | 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類 |
| GB2427405A (en) | 2004-04-07 | 2006-12-27 | Pharmacyclics Inc | Novel hydroxamates as therapeutic agents |
| EP1591109B1 (en) | 2004-04-30 | 2008-07-02 | TopoTarget Germany AG | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
| WO2005117980A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| CA2575557A1 (en) | 2004-07-30 | 2006-02-09 | Rosetta Inpharmatics Llc | Prognosis of breast cancer patients |
| WO2006042035A2 (en) | 2004-10-07 | 2006-04-20 | Pharmacyclics, Inc. | Method of monitoring anti-tumor activity of an hdac inhibitor |
| TW200621240A (en) * | 2004-11-05 | 2006-07-01 | Salmedix Inc | Cancer treatments |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2006101454A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
| US8338416B2 (en) | 2006-03-16 | 2012-12-25 | Pharmacylics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| AU2007296256B2 (en) | 2006-09-15 | 2013-05-30 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors with combined activity on class-I and class-IIB histone deacetylases in combination with proteasome inhibitors |
| EP2626067A1 (en) | 2006-12-26 | 2013-08-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| US7838234B2 (en) | 2007-01-30 | 2010-11-23 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| UY34295A (es) | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
| EP3027192A4 (en) | 2013-08-02 | 2017-03-22 | Pharmacyclics, LLC | Methods for the treatment of solid tumors |
-
2011
- 2011-09-13 CN CN201180074826.7A patent/CN103917231B/zh active Active
- 2011-09-13 CA CA2845806A patent/CA2845806C/en active Active
- 2011-09-13 US US14/344,314 patent/US9492423B2/en active Active
- 2011-09-13 RU RU2014111069A patent/RU2609833C2/ru not_active IP Right Cessation
- 2011-09-13 SG SG2014014419A patent/SG2014014419A/en unknown
- 2011-09-13 KR KR1020147007117A patent/KR101892788B1/ko not_active Expired - Fee Related
- 2011-09-13 EP EP11872389.9A patent/EP2755648B1/en active Active
- 2011-09-13 WO PCT/US2011/051470 patent/WO2013039488A1/en not_active Ceased
- 2011-09-13 ES ES11872389.9T patent/ES2627820T3/es active Active
- 2011-09-13 MX MX2014002942A patent/MX365393B/es active IP Right Grant
- 2011-09-13 UA UAA201402905A patent/UA110853C2/uk unknown
- 2011-09-13 NZ NZ621221A patent/NZ621221A/en not_active IP Right Cessation
- 2011-09-13 JP JP2014530636A patent/JP6330118B2/ja active Active
- 2011-09-13 AU AU2011376953A patent/AU2011376953B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| UA110853C2 (uk) | 2016-02-25 |
| US9492423B2 (en) | 2016-11-15 |
| MX365393B (es) | 2019-05-31 |
| SG2014014419A (en) | 2014-07-30 |
| EP2755648B1 (en) | 2017-03-08 |
| AU2011376953A1 (en) | 2014-03-06 |
| ES2627820T3 (es) | 2017-07-31 |
| CN103917231A (zh) | 2014-07-09 |
| EP2755648A1 (en) | 2014-07-23 |
| JP6330118B2 (ja) | 2018-05-30 |
| EP2755648A4 (en) | 2015-03-11 |
| AU2011376953B2 (en) | 2017-08-24 |
| KR20140073503A (ko) | 2014-06-16 |
| JP2014526503A (ja) | 2014-10-06 |
| CA2845806C (en) | 2019-06-11 |
| RU2609833C2 (ru) | 2017-02-06 |
| CN103917231B (zh) | 2016-09-28 |
| HK1200095A1 (en) | 2015-07-31 |
| CA2845806A1 (en) | 2013-03-21 |
| MX2014002942A (es) | 2014-09-15 |
| KR101892788B1 (ko) | 2018-08-28 |
| US20140341989A1 (en) | 2014-11-20 |
| WO2013039488A1 (en) | 2013-03-21 |
| RU2014111069A (ru) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ621221A (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
| HUS1900018I1 (hu) | Gyûrûs boronsavészter-származékok és terápiás alkalmazásuk | |
| NZ603151A (en) | N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| PE20140252A1 (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| IL231203A0 (en) | Novel selective and reversible ubiquitin-specific inhibitors of protease 7, their pharmaceutical preparations and their therapeutic applications | |
| EP2751086A4 (en) | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF | |
| EA201270254A1 (ru) | Производные 5-фторпиримидинона | |
| MX2013000642A (es) | Composiciones farmaceuticas. | |
| IN2012DN00692A (OSRAM) | ||
| BR112013031794A2 (pt) | novos derivados de oxintomodulina e composição farmacêutica para o tratamento da obesidade compreendendo os mesmos | |
| UY33754A (es) | Monobactamas | |
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. | |
| WO2011131943A3 (en) | Pharmaceutical compositions | |
| GEP20125650B (en) | Thiophene or thiazole derivatives and use thereof as pi3k inhibitors | |
| WO2011117034A3 (de) | Kosmetische oder dermatologische zubereitungen mit einem gehalt an einem oder mehreren thiazolderivaten | |
| EP2750677A4 (en) | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD OF USE THEREOF | |
| HUE036287T2 (hu) | Vegyület új kalciumsói gyulladásellenes, immunmoduláns és antiproliferatív szerekként | |
| PH12013501561A1 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| BR112013014189A8 (pt) | composição farmacêutica, uso de um agente de potencialização e uso de uma composição | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| AU2016204294A1 (en) | Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor | |
| EA201590028A1 (ru) | Ингибиторы гистондеацетилазы и их композиции и способы их применения | |
| CL2013000788A1 (es) | Compuestos derivados de 1,2,4-oxadiazol, inhibidores de la proteina activadora de 5-lipoxigenasa (flap); composicion farmaceutica; metodo de tratamiento; y uso para el tratamiento de un trastorno mediado por leucotrienos tal como enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas, renales y cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: PHARMACYCLICS, INC., US Effective date: 20150423 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 SEP 2018 BY SPRUSON + FERGUSON Effective date: 20161130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2019 BY COMPUTER PACKAGES INC Effective date: 20180818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 SEP 2020 BY COMPUTER PACKAGES INC Effective date: 20190820 |
|
| LAPS | Patent lapsed |